650nm low-intensity red light targets eye mitochondria. It activates cytochrome c oxidase to generate more ATP energy, boosts choroidal blood circulation and thickens choroid tissue. It regulates retinal dopamine secretion to slow eye axial growth, effectively controlling the deepening of juvenile myopia. Safe for daily home use.
Mitochondrial energy activation: 650nm wavelength matches the absorption spectrum of cytochrome c oxidase (CCO) inside retinal mitochondria. It dissociates inhibitory nitric oxide, accelerates electron transport chain and elevates intracellular ATP production, repairing metabolically damaged retinal cells and alleviating ocular hypoxia caused by heavy near-work.
Choroidal vascular improvement: Enhanced blood perfusion thickens the choroid layer, which provides sufficient nutrition to the sclera and suppresses abnormal scleral elongation, the root cause of progressive myopia.
Neurotransmitter regulation: Optimized light stimulation promotes dopamine release from retinal amacrine cells. Dopamine inhibits the biochemical signal that triggers excessive axial growth, reducing the risk of high myopia and related fundus complications such as retinal detachment and glaucoma.
This device works synergistically with the dynamic accommodation trainer to build a dual myopia control system: one improves eye accommodation function, the other optimizes fundus microcirculation to jointly delay myopia advancement.
